Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733415 | 0.97 | MAPT (0.36) | FFAR2MAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL20203621 | 0.86 | TDP1 (0.37) | FFAR2MAPTTDP1JAK2JAK3 | |
| SCHEMBL20203413 | 0.80 | MAPK1 (0.39) | MAPTTDP1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL23733416 | 0.80 | POLB (0.43) | MAPTMAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20203535 | 0.80 | MAPT (0.38) | MAPTTDP1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL20203412 | 0.79 | LMNA (0.43) | MAPTTDP1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL23733440 | 0.78 | MAPK1 (0.39) | MAPTTDP1JAK3MAPK1SMN1; SMN2 | |
| SCHEMBL23733436 | 0.78 | MAPT (0.36) | MAPTTDP1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL23733420 | 0.77 | JAK2 (0.41) | MAPTTDP1JAK2JAK3MAPK1 | |
| SCHEMBL20203486 | 0.77 | TP53 (0.40) | MAPTTDP1MAPK1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | FFAR2 4497/4885MAPT 2593/4885TDP1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.